Activation of p53 tumor suppressor by hepatitis C virus core protein

被引:119
作者
Lu, W
Lo, SY
Chen, M
Wu, KJ
Fung, YKT
Ou, JH
机构
[1] Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA
[2] Childrens Hosp Los Angeles, Dept Pediat & Hematol, Los Angeles, CA 90027 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1006/viro.1999.9979
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In addition to being a structural protein that packages the viral genomic RNA, hepatitis C virus (HCV) core protein possesses regulatory functions. In this report, we demonstrate that the HCV core protein could enhance the gene transactivation activity of the tumor suppressor p53, regardless of whether p53 was derived from an exogenous or an endogenous gene. The activation of p53 by the HCV core protein was supported by the observation that the HCV core protein could enhance the expression of p21(waf1/Cip1), a downstream effector gene of p53, in a p53-dependent manner. Further studies indicated that the HCV core protein could also suppress hepatocellular growth via p53. The HCV core protein and p53 could bind to each other in vitro, which was evidenced by the coimmunoprecipitation, the GST pull-down, and the Far-Western blot assays. The deletion-mapping analysis indicated that the carboxy-terminal sequence of p53 located between amino acids 366 and 380 was required for the core protein binding. These results raised the possibility that the HCV core protein might activate p53 through direct physical interaction. The persistent perturbation of p53 activity by the HCV core protein during chronic infection may have important consequences in HCV pathogenesis. (C) 1999 Academic Press.
引用
收藏
页码:134 / 141
页数:8
相关论文
共 34 条
[1]   ABNORMAL STRUCTURE AND EXPRESSION OF P53 GENE IN HUMAN HEPATOCELLULAR-CARCINOMA [J].
BRESSAC, B ;
GALVIN, KM ;
LIANG, TJ ;
ISSELBACHER, KJ ;
WANDS, JR ;
OZTURK, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (05) :1973-1977
[2]   Hepatitis C virus core from two different genotypes has an oncogenic potential but is not sufficient for transforming primary rat embryo fibroblasts in cooperation with the H-ras oncogene [J].
Chang, J ;
Yang, SH ;
Cho, YG ;
Hwang, SB ;
Hahn, YS ;
Sung, YC .
JOURNAL OF VIROLOGY, 1998, 72 (04) :3060-3065
[3]   Expression of cyclin-dependent kinase inhibitor p21 in human liver [J].
Crary, GS ;
Albrecht, JH .
HEPATOLOGY, 1998, 28 (03) :738-743
[4]   Ethanol and hepatocellular injury [J].
French, SW .
CLINICS IN LABORATORY MEDICINE, 1996, 16 (02) :289-+
[5]   Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells [J].
Friedman, SL ;
Shaulian, E ;
Littlewood, T ;
Resnitzky, D ;
Oren, M .
ONCOGENE, 1997, 15 (01) :63-70
[6]   Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain [J].
Gu, W ;
Roeder, RG .
CELL, 1997, 90 (04) :595-606
[7]   CHARACTERIZATION OF THE HEPATITIS-B VIRUS ENHI ENHANCER AND X-PROMOTER COMPLEX [J].
GUO, WT ;
BELL, KD ;
OU, JH .
JOURNAL OF VIROLOGY, 1991, 65 (12) :6686-6692
[8]  
HACHIYA M, 1994, ANTICANCER RES, V14, P1853
[9]  
Jiang MC, 1996, ONCOGENE, V13, P609
[10]   Transgenic expression of hepatitis C virus structural proteins in the mouse [J].
Kawamura, T ;
Furusaka, A ;
Koziel, MJ ;
Chung, RT ;
Wang, TC ;
Schmidt, EV ;
Liang, TJ .
HEPATOLOGY, 1997, 25 (04) :1014-1021